SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amid mixed sentiment, with some investors expressing concerns about the company's financial outlook and others highlighting the quality of its vehicles and potential partnerships; community discussions revolve around production targets, competition in the EV market, and the impact of a recent reverse stock split.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending due to its unique blend of meme culture and real-world utility through Cocky Wings, a food truck business that drives token buybacks. The community is actively discussing the passive income opportunities in the $COCK Arena and the upcoming $SNEK energy drink partnership. This project stands out with its real-world asset backing and engaging community initiatives, differentiating it from typical memecoins.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica ($CLS) is trending due to strong performance in the AI infrastructure market, with analysts highlighting its potential for further growth and comparing it to an early-stage Nvidia. Community discussions emphasize Celestica's key role in enabling Broadcom's AI networking stack and benefiting from AMD's quantum computing advancements, leading to increased investor interest and options activity. Earnings are coming up, adding to the volatility.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending amid discussions about its recent performance and potential Coinbase listing, with the community highlighting its limited supply of one million tokens. Some users are reporting issues with trading on Coinbase, while others speculate on possible price movements and future rallies. The token's association with AI tools and the broader Base App ecosystem are also points of interest.

The ArcBlock project was created to create the first Blockchain ecosystem in the world. Develop and develop decentralized applications (DApp) according to objectives. ArcBlock, one of the ICO projects emerging in early 2018. Just launched on 3/1/2018, ArcBlock has quickly attracted the attention of technology as well as investors. ArcBlock brings great technological advancements that will open the third generation of blockchain applications.  Arcblock work by bridging the gap between different blockchains and their respective ecosystems has not been easy. There are some solutions which attempt to solve this problem, but it is evident there is plenty of room for competition in this regard. Building an open chain access layer capable of spanning multiple new and existing blockchains is a very interesting business model.  Building a new ecosystem meant to connect various chains will not be easy. As of right now, the team has completed its token sale, and the first public release candidate for the Open Chain Access Protocol will be released in Q3. Early 2019 will herald the introduction of more technical features and an Ethereum Blocklet prototype.

ABT is trending amidst community frustration with price action and disappointment in 

Ball Corp. engages in the supplies of aluminum packaging for the beverage, personal care, and household products industries. It operates through the following segments: Beverage Packaging North and Central America, Beverage Packaging South America, and Beverage Packaging Europe, Middle East and Africa (EMEA). The Beverage Packaging North and Central America segment includes multi-year supply contracts to fillers of carbonated soft drinks, beer, energy drinks, and other beverages. The Beverage Packaging South America segment includes beverage containers in South America, and the manufacture of substantially all the metal beverage containers in Brazil. The Beverage Packaging EMEA segment consists of metal beverage containers in Europe, and other packaging materials used by the European beer and carbonated soft drink industries. The company was founded by Edmund Burke Ball, Frank Clayton Ball, George A. Ball, Lucius Lorenzo Ball, and William Charles Ball in 1880 and is headquartered in Westminster, CO.

Ball Corp.

BALL is trending amid multiple analyst target price cuts and ratings adjustments, alongside news of the completed sale of its Russian beverage packaging business. The community is closely watching the stock's reaction to these developments and a management briefing, with some investors expressing long-term confidence despite near-term headwinds. Discussions also involve the company's sustainability initiatives and potential reinvestment of proceeds from the Russian sale.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma ($XPL) is trending amid discussions about its listing on a Chinese exchange and the broader implications of stablecoin developments, including a Federal Reserve conference on the topic. Community members are weighing the potential impact of these events, with some pointing to its underlying technology and others expressing caution due to recent price volatility. There is also discussion around potential connections to other projects and exchanges.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is trending as investors analyze potential impacts from upcoming earnings and broader healthcare sector dynamics. Community discussions revolve around expectations for premium growth and Optum's performance, with some bracing for a possible dip while others anticipate a post-earnings surge. Takeover speculation, analyst ratings, and the potential effect of government subsidies are also being heavily discussed.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors discuss the recent pullback and potential for a rebound. Community members are pointing to upcoming earnings and broader sector trends, along with potential deregulation, as possible catalysts while closely monitoring insider activity and institutional investment.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL (GRAL) is trending due to positive results from its PATHFINDER 2 study, showcasing strong performance in early cancer detection, as well as a presentation at the Jefferies Global Healthcare Conference on Wednesday. Community discussions revolve around the test's potential, upcoming milestones, and the possibility of Medicare coverage, with some comparing GRAL to other high-growth potential biotech stocks. There is also chatter around a short report and whether the company will pursue a share offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a late-stage trial evaluating the drug in the treatment of women with newly diagnosed advanced ovarian cancer.Shares of the company traded 4% higher in morning trade at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMNN">IMUNON</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_9_43_26_AM_png_dc891d230b.webp" alt="IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company is undervalued.<stembedurl>https://stocktwits.com/ConcernedCitizen23/message/623007565</stembedurl>The late-stage <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.imunon.com/news-releases/news-release-details/imunon-announces-first-patient-dosed-phase-3-ovation-3-study">study</a> is aimed at assessing the safety and efficacy of IMNN-001 plus standard of care neoadjuvant and adjuvant chemotherapy of Paclitaxel and Carboplatin compared to standard of care chemotherapy alone.The primary endpoint of the study is overall survival or lengthening the lifespan of patients.The study will also check secondary endpoints such as surgical response score, chemotherapy response score, clinical response, and time to second-line treatment.“We have great urgency around this program because patients do not have any other options besides the standard of care, which includes neoadjuvant and adjuvant chemotherapy and surgery,” CEO Stacy Lindborg said.According to IMUNON, epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year, and approximately 70% are diagnosed in advanced Stage III/IV, the company said.Earlier this month, IMUNON completed a reverse stock split of its issued and outstanding common stock at a ratio of 1:15 to meet the minimum bid price requirement for continued listing on the Nasdaq.IMNN stock is down by 43% this year and by about 84% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 

Equity

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 


Imunon hit its highest levels in nearly three years Tuesday, fueled by its announcement to present Phase 2 OVATION 2 study immune biomarker data at the European Society for Medical Oncology Gynaecological Cancers Congress 2025.The accepted abstract presents the results of IMNN-001, an IL-12 gene therapy developed from Imunon's TheraPlas platform, used in conjunction with neoadjuvant and adjuvant chemotherapy treatments for newly diagnosed, advanced ovarian cancer patients.Imunon shares surged 95.69% to close at $2.27 on May 27, before pulling back 23.35% in after-hours trading to $1.74.Premal H. Thaker, the chair of the Ovation 2 and 3 study, will deliver the presentation at the June 19–21 Vienna-based congress.The announcement follows recent news that new Ovation 2 data will also be featured in an oral presentation at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.&nbsp;These results showed meaningful increases in overall and progression-free survival for the IMNN-001 treatment group, with a median 13-month improvement in overall survival.CEO Stacy Lindborg called the data “remarkable” and said the growing interest from EU and Latin American researchers reinforces confidence in the company’s Phase 3 Ovation 3 trial and regulatory ambitions.&nbsp;The Phase 3 Ovation 3 trial, which recently initiated its first two sites, will evaluate IMNN-001 plus chemotherapy versus chemotherapy alone in patients with Stage IIIC or IV epithelial ovarian cancer.&nbsp;The primary endpoint is overall survival.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,554% surge in 24-hour message volume.One user commented that anyone worried about the after-hours drop should note that the stock behaved similarly last Friday, followed by a strong run the next day.&nbsp;<stembedurl>https://stocktwits.com/NFD2/message/615992363</stembedurl>Another user highlighted the possibility of an upcoming press release announcing a major partnership with a big pharmaceutical company to support funding and potential licensing or commercialization deals, citing CEO comments from recent weeks.<stembedurl>https://stocktwits.com/gourmetmacncheese/message/615991264</stembedurl>The stock has risen 116% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon

The data highlights promising results for IMNN-001, an IL-12 gene therapy for advanced ovarian cancer, boosting investor optimism ahead of its Phase 3 trial.

Retail buzz around Imunon rose sharply Thursday after the clinical-stage biotech company said it will no longer pursue a previously planned public offering.&nbsp;Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4.The biotech firm's shares rose 4.1% to $0.42 on Thursday and surged another 15.5% in after-hours trading to $0.48.The news follows a first-quarter (Q1) financial update, which showed that Imunon decreased its net loss from $4.9 million last year to $4.1 million.Imunon reported a per-share loss of $0.28, below the consensus estimate of $0.36.R&amp;D cost reductions totaling $1.1 million drove an 18% decrease in operating expenses, bringing the total to $4.1 million.&nbsp;The decline was driven by spending reductions on the Ovation 2 study, the PlaCCine DNA vaccine trial, and platform development activities.Employee-related costs&nbsp;increased, causing general and administrative expenses to rise slowly to $2.0 million from $1.7 million last year, although lower legal fees helped partially offset this increase.The operating activities required $2.8 million in cash, a reduction of more than half compared to the $5.9 million used in Q1 2024.As of quarter-end, Imunon maintained $2.9 million in cash reserves and projects that these funds will support operations until late Q2 2025.CEO Stacy Lindborg highlighted clinical advancements, including the Ovation 3 pivotal study and ongoing results from the Ovation 2 trial, which showed that the DNA-based immunotherapy IMNN-001 increased progression-free and overall survival rates among patients newly diagnosed with ovarian cancer.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,120% surge in 24-hour message volume.One user suggested the move implies management may have “a much better option for funding,” citing recent earnings call comments from the CEO about active financing and partnership discussions.&nbsp;<stembedurl>https://stocktwits.com/ItTakesItAll/message/615624018</stembedurl>Another user called the update “great news,” pointing to the company’s low float.<stembedurl>https://stocktwits.com/ItTakesItAll/message/615621205</stembedurl>The stock has declined 60.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’

Shares jumped 15.5% after hours, as retail traders pointed to “much better funding options” hinted at during the firm’s recent earnings call.

Earnings Outlook For Imunon

Equities Analysts Issue Forecasts for Imunon, Inc.'s Q1 2024 Earnings (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Imunon in a research report issued to clients and investors on Monday...

Imunon, Inc. (NASDAQ:IMNN) Short Interest Down 8.6% in March

Imunon, Inc. (NASDAQ:IMNN - Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 449,100 shares, a drop of 8.6% from...

Imunon price target raised by $1 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Q4 2023 Imunon Inc Earnings Call Transcript

Imunon sees cash runway into 4Q24

Imunon reports 2023 EPS ($2.16) vs. ($5.03) last year

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Imunon Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

IMNN
Imunon Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IMNN News

IMNNImunon Inc